EAM Investors’s Trevi Therapeutics TRVI Stock Holding History

EAM Investors’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.94M	Buy	+264,631	New	+$3.85M	0.44%	106
2026 Q1	–	Sell	-541,242	Closed	-$6.78M	–	375
2025 Q4	$6.78M	Sell	541,242 -8,237	-1%	-$95.2K	0.75%	19
2025 Q3	$4.97M	Buy	549,479 +62,855	+13%	+$471K	0.57%	60
2025 Q2	$2.66M	Sell	486,624 -64,295	-12%	-$400K	0.4%	123
2025 Q1	$3.47M	Buy	+550,919	New	+$2.63M	0.6%	69
2022 Q4	–	Sell	-58,202	Closed	-$90K	–	343
2022 Q3	$90K	Sell	58,202 -315,041	-84%	-$1.03M	0.02%	246
2022 Q2	$1.05M	Buy	+373,243	New	+$917K	0.26%	185

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

EAM Investors's TRVI Position: Q2 2026 in Review

EAM Investors opened a new position in Trevi Therapeutics (TRVI) in Q2 2026: 264,631 shares worth $4.94M. The stake represents 0.44% of the portfolio and ranks #106 among its holdings. This is a return to the name: EAM Investors previously reported a position in TRVI as recently as Q4 2025.

EAM Investors first reported a position in TRVI in Q2 2022 and has held it in 7 quarters since. The position peaked at $6.78M in Q4 2025. 219 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

EAM Investors held 264,631 shares of Trevi Therapeutics worth $4.94M as of Q2 2026.
Trevi Therapeutics was a new EAM Investors position in Q2 2026.
Trevi Therapeutics made up 0.44% of EAM Investors's portfolio in Q2 2026, its #106 holding.
EAM Investors first reported a position in Trevi Therapeutics in Q2 2022 and has held it in 7 quarters since.
EAM Investors's Trevi Therapeutics position peaked at $6.78M in Q4 2025.
219 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on EAM Investors's 13F filing for Q2 2026, filed 13 Aug 2026.